Search Results for: lrrk2

Parkinson's research

LRRK2 Therapies May Be Useful for Wider Population

Monday, 30 July 2018

New research findings show a role for the LRRK2 protein in Parkinson’s disease among people without a LRRK2 genetic mutation. These results mean that drugs in development targeting LRRK2 might also benefit people without the mutation. Researchers study genetic mutations linked to…

Parkinson's research

LRRK2 Drug Trial Show Promising Results

Monday, 8 January 2018

Denali Therapeutics has announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The trial concluded that the experimental treatment is safe, and showed a greater than 90 percent inhibition of LRRK2 activity at peak drug levels while lowered the LRRK2…

New Research Confirms Role of LRRK2 in Immune Cells

Monday, 10 April 2017

Though associated with only a small percentage of total Parkinson’s cases, mutations of the LRRK2 gene are the greatest known genetic contributor to Parkinson’s disease (PD). Researchers are striving to understand the mechanisms of disease related to this mutation because…

Parkinson's research

Another Leap Forward for LRRK2 Development

Monday, 29 August 2016

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…

Scientists Discover Potential Pathway of LRRK2 Dysfunction

Tuesday, 15 April 2014

Researchers from Johns Hopkins University have reported on a potential route through which mutations in the LRRK2 gene — the greatest known genetic contributor to Parkinson’s disease (PD) — lead to cell death. This finding comes as much of the…

Iwona Strycharska-OrzyMJFF Launches Access to LRRK2 Resources to Accelerate Discovery

MJFF Launches Access to LRRK2 Resources to Accelerate Discovery

Tuesday, 2 July 2013

In an effort to advance research and collaborate toward a cure, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is pioneering an innovative approach to accelerate drug development around the LRRK2 gene. Since 2009, MJFF has brought together international…

Scientists Find New Marker to Measure LRRK2 Activity

Scientists Find New Marker to Measure LRRK2 Activity

Tuesday, 18 December 2012

The protein leucine-rich repeat kinase 2, or LRRK2, is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of reasons: For one, mutations in the gene associated with LRRK2 are…

LRRK2 Physiology in Parkinson’s Disease

Thursday, 15 March 2012

  Date:            November 2011 Location:   Neuroscience Research Australia Prof Glenda Halliday & Dr Nic Dzamko Objective/Rationale: Mutations in the LRRK2 gene are a common cause of genetic Parkinson’s disease. LRRK2 is highly expressed in…

Genetics and Parkinson's

Is Parkinson’s Genetic

Wednesday, 10 October 2018

Two decades ago, researchers established that Parkinson’s has a genetic connection. Since then, genetic research has opened up a whole new world of possibilities for understanding, diagnosing and treating Parkinson’s disease (PD). It’s uncovering Parkinson’s pathways and guiding development of…

Genetics and Parkinson’s – PRKN and PINK1 Genes

Monday, 10 September 2018

Learning about genetic risk factors for Parkinson’s can help scientists learn what goes wrong in the disease — even among those without those risk factors — and how they might fix it. Thanks to this strategy, treatments are now in…